Effect of Natalizumab on Disease Progression in Secondary Progressive Multiple Sclerosis (ASCEND): A Phase 3, Randomised, Double-Blind, Placebo-Controlled Trial With an Open-Label Extension

The Lancet Neurology - United Kingdom
doi 10.1016/s1474-4422(18)30069-3
Full Text
Abstract

Available in full text

Categories
Neurology
Date
Authors
Publisher

Elsevier BV

Related search

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

New England Journal of Medicine
Medicine
2006English

Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial

The Lancet
Medicine
2012English

OP0208 a Proof-Of-Concept Double-Blind Randomised Placebo-Controlled Trial of Probiotics in Systemic Sclerosis Associated Gastrointestinal Disease

2018English

Etanercept in Alzheimer Disease: A Randomized, Placebo-Controlled, Double-Blind, Phase 2 Trial

Neurology
Neurology
2015English

Limited Effect of Sulphasalazine Treatment in Reactive Arthritis. A Randomised Double Blind Placebo Controlled Trial

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
1997English

Randomised, Double-Blind, Placebo-Controlled Trial of EPs 7630 in Adults With COPD

Respiratory Medicine
PulmonaryRespiratory Medicine
2013English

Tocilizumab in Patients With Adult-Onset Still’s Disease Refractory to Glucocorticoid Treatment: A Randomised, Double-Blind, Placebo-Controlled Phase III Trial

Annals of the Rheumatic Diseases
ImmunologyMolecular BiologyBiochemistryRheumatologyAllergyGenetics
2018English

Bumetanide in Hypokalaemic Periodic Paralysis: A Randomised, Double-Blind, Placebo Controlled Phase II Clinical Trial With a Crossover Design

Neuromuscular Disorders
Child HealthNeurologyPediatricsPerinatologyGenetics
2016English

Adalimumab for Nail Psoriasis: Efficacy and Safety From the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

SKIN The Journal of Cutaneous Medicine
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy